| Harringtoninenatural alkaloid that inhibits protein synthesis |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity ≥ 95.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Harringtonine Dilution Calculator
calculate
Harringtonine Molarity Calculator
calculate
| Cas No. | 26833-85-2 | SDF | Download SDF |
| Synonyms | NSC 124147 | ||
| Chemical Name | 3-[4-methyl (2R)-2-hydroxy-2-(3-hydroxy-3-methylbutyl)butanedioate]cephalotaxine | ||
| Canonical SMILES | O=C(OC)C[C@@](CCC(C)(O)C)(O)C(O[C@H]1[C@](C(C=C(OCO2)C2=C3)=C3CCN4CCC5)([H])[C@]45C=C1OC)=O | ||
| Formula | C28H37NO9 | M.Wt | 531.6 |
| Solubility | ≤25mg/ml in ethanol;25mg/ml in DMSO;25mg/ml in dimethyl formamide | Storage | Store at -20°C |
| Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
Harringtonine is a protein synthesis inhibitor [1].
Harringtonine, homoharringtonine and isoharringtonine are alkaloids from Cephalotaxus harringtonia. They have an antitumour activity due to their inhibitory effect on protein synthesis and differ only in a side chain [1].
Harringtonine is a natural alkaloid from Cephalotaxus harringtonia that inhibits protein synthesis in eukaryotic cells. Harringtonine inhibit the initiation of polypeptide synthesis. Harringtonine blocks peptide bond formation and aminoacyl-tRNA binding [1][2]. Harringtonine also immobilizes ribosomes immediately after translation initiation, which can be used to capture ribosome-protected mRNA fragments for evaluating translation [2]. The homolog of harringtonine, homoharrington inhibited the first steps of elongation and rapidly degraded short-lived proteins. In Pten+/- Eμ-Myc lymphomas, homoharrington blocked translation and reduced levels of Mcl-1, Cyclin D1, and c-Myc.
In mice with BCR-ABL-induced CML, homoharrington (also known as omacetaxine) significantly reduced the numbers of both LSCs and total leukemia cells [3][4].
References:[1]. Fresno M, Jiménez A, Vázquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem. 1977 Jan;72(2):323-30.[2]. Ingolia NT, Brar GA, Rouskin S, et al. The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments. Nat Protoc. 2012 Jul 26;7(8):1534-50.[3]. Kantarjian HM, O"Brien S, Anderlini P, et al. Treatment of myelogenous leukemia: current status and investigational options. Blood. 1996 Apr 15;87(8):3069-81.[4]. Chen Y, Peng C, Sullivan C, et al. Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Anticancer Agents Med Chem. 2010 Feb;10(2):111-5.
